Core Viewpoint - A class action lawsuit has been filed against Alight, Inc. for alleged securities fraud and unlawful business practices, with investors encouraged to join the lawsuit by May 15, 2026 [1][2]. Financial Performance - On August 5, 2025, Alight reported disappointing second-quarter results, cutting its revenue guidance for the year, citing a slowdown in annual recurring revenue bookings and a more significant decline in project revenue than expected. Following this announcement, Alight's stock price dropped by $0.94, or 18.32%, closing at $4.19 per share on August 4, 2025 [4]. - On February 19, 2026, Alight reported a fourth-quarter earnings miss, revealing customer renewal rates significantly below prior targets and projecting further revenue declines into early 2026. The company eliminated its quarterly dividend, did not provide full-year guidance, and recorded a substantial multibillion-dollar goodwill impairment, negatively impacting its balance sheet [5]. - Following the February 19 announcement, Alight's stock price fell by $0.50, or 38.17%, closing at $0.81 per share [6].

Core Viewpoint - The Super Micro Computer, Inc. (SMCI) is facing a class action lawsuit due to allegations of securities violations related to misleading statements and non-disclosure of significant sales to Chinese companies, which allegedly violated U.S. export control laws [1][4]. Company Overview - Super Micro Computer, Inc. develops and sells server and storage solutions based on modular and open-standard architecture [3]. Allegations - The lawsuit claims that Super Micro and its executives made false statements and failed to disclose that a significant portion of their server sales were to companies in China, which violated U.S. export control laws [4]. - It is alleged that there were material weaknesses in Super Micro's compliance controls regarding export regulations [4]. - The U.S. Department of Justice announced an indictment against three individuals associated with Super Micro for diverting servers containing U.S. AI technology to China, resulting in approximately $2.5 billion worth of sales between 2024 and 2025 [5]. Impact on Stock - Following the DOJ announcement, Super Micro's stock price fell by more than 33% [5].

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged securities fraud and unlawful business practices, with investors encouraged to join the lawsuit by contacting Pomerantz LLP [1][2]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Ultragenyx and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until April 6, 2026, to request to be appointed as Lead Plaintiff if they purchased Ultragenyx securities during the Class Period [2]. Group 2: Stock Performance and Events - On July 9, 2025, Ultragenyx announced progress in the Phase 3 Orbit study for UX143, leading to a stock price drop of $10.41 per share, or 25.11%, closing at $31.04 on July 10, 2025 [4]. - On December 29, 2025, Ultragenyx reported that its Phase III Orbit and Cosmic Studies failed to achieve statistical significance, resulting in a stock price decline of $14.47 per share, or 42.32%, closing at $34.19 [5].

Core Viewpoint - A class action lawsuit has been filed against Pinterest, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from February 7, 2025, to February 12, 2026, seeking damages for affected investors [1]. Company Overview - Pinterest is a visual social media platform where users organize content into "boards" that often include products or services from advertisers [4]. - The platform offers a unique value proposition to advertisers by focusing on users' interests in products and services rather than social connections [5]. - Pinterest generates nearly all of its revenue from advertising, with a significant portion coming from a small number of advertisers, particularly in retail and consumer packaged goods [6]. Allegations and Misstatements - Throughout the Class Period, Pinterest's executives allegedly made materially false and misleading statements regarding the company's business and operations, including overstating its ability to manage the impact of U.S. tariffs on advertising revenues [8]. - The complaint claims that Pinterest was likely to experience reduced revenues from advertising partners and that the company was facing an imminent restructuring due to these issues [8]. Financial Performance and Stock Impact - On November 4, 2025, Pinterest announced Q4 revenue guidance of $1.325 billion, which was below consensus expectations of $1.34 billion, leading to a stock price drop of $7.16 per share (21.76%) [9][10]. - On January 27, 2026, Pinterest revealed a global restructuring plan affecting less than 15% of its workforce, anticipating pre-tax restructuring charges of approximately $35 million to $45 million, resulting in a stock price decline of $2.49 per share (9.61%) [11]. - On February 12, 2026, Pinterest reported quarterly revenue of $1.32 billion, below the consensus estimate of $1.33 billion, and provided Q1 2026 revenue guidance of $951 million to $971 million, also below expectations, causing a further stock price drop of $3.12 per share (16.83%) [12][13].

Core Viewpoint - A class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from October 10, 2023, to December 26, 2025, seeking damages for investors who purchased Inovio securities during this time [1] Company Overview - Inovio Pharmaceuticals is a biotechnology company focused on developing DNA medicines to treat diseases, including those associated with human papilloma virus (HPV) [4] - The company's lead product candidate is INO-3107, aimed at treating recurrent respiratory papillomatosis (RRP), a rare disease caused by HPV [5] Product Development and Regulatory Issues - Defendants had previously indicated that they expected the FDA to grant accelerated approval for INO-3107 and aimed to complete the rolling submission of its Biologics License Application (BLA) by the second half of 2024 [5] - However, it was later revealed that manufacturing issues with the CELLECTRA device would delay the BLA submission to mid-2025, representing a full-year delay from the initial timeline [8] Stock Performance and Market Reaction - Following the announcement of the delay in BLA submission on August 8, 2024, Inovio's stock price fell by $0.27 per share, or 3.1%, closing at $8.44 per share [9] - On December 29, 2025, the FDA accepted the INO-3107 BLA on a standard review timeline instead of an accelerated one, leading to a significant drop in stock price by $0.56 per share, or 24.45%, closing at $1.73 per share [10][11] Misleading Statements - Throughout the Class Period, Defendants allegedly made materially false and misleading statements regarding the company's operations and prospects, including deficiencies in manufacturing and overstated regulatory and commercial prospects for INO-3107 [7]

Core Viewpoint - A class action lawsuit has been filed against Gemini Space Station, Inc. and certain officers for alleged violations of federal securities laws related to its initial public offering and subsequent business operations [1]. Company Overview - Gemini was founded in 2014 to develop and operate a cryptocurrency platform [3]. - The company primarily generates revenue through transaction, deposit, and other fees charged to users of its crypto platform [4]. IPO and Offering Documents - Gemini's Class A common stock began trading on NASDAQ under the ticker symbol "GEMI" on September 12, 2025, with 15,178,572 shares issued at an offering price of $28.00 per share, raising approximately $398.4 million before expenses [6][7]. - The Offering Documents represented that Gemini was focused on expanding its exchange platform by increasing monthly transacting users (MTUs), average daily trading volume, and the number of assets available [4]. Allegations of Misrepresentation - The Offering Documents allegedly contained untrue statements and omitted necessary facts, leading to claims that Gemini overstated the viability of its core business and its commitment to international expansion [8]. - Throughout the class period, the company reportedly made materially false and misleading statements regarding its business operations and prospects [8]. Corporate Changes and Market Reaction - On February 5, 2026, Gemini announced a significant corporate pivot to a prediction market model, which included a 25% workforce reduction and exiting several international markets [10]. - Following this announcement, Gemini's stock price fell by 8.72% to close at $6.70 per share [11]. - On February 17, 2026, the company reported preliminary financial results indicating net revenue of $165 million to $175 million and operating expenses of $520 million to $530 million, marking a 40% increase from the previous fiscal year [12]. Impact of Leadership Changes - The departure of key executives, including the COO and CFO, was linked to the company's restructuring efforts, further impacting investor confidence and stock performance [12][13].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Pinterest, Inc. securities between February 7, 2025, and February 12, 2026, alleging securities fraud due to misleading statements made by the company [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Pinterest made false and misleading statements regarding its advertising revenues and the impact of U.S. tariffs on its business operations [5]. - The lawsuit alleges that Pinterest was likely to experience reduced revenues from advertising partners and that the company overstated its ability to manage macroeconomic impacts [5]. - It is claimed that the misleading statements led to significant damages for investors when the true situation was revealed [5]. Group 2: Participation Information - Investors who purchased Pinterest securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by May 29, 2026, to represent the interests of the class members in the lawsuit [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 alone [4]. - The firm has been recognized for its success in securities class action settlements and has been ranked highly in the field since 2013 [4].

Core Viewpoint - Grabar Law Office is investigating claims on behalf of shareholders of Super Micro Computer, Inc. regarding potential breaches of fiduciary duties by certain officers of the company [1]. Group 1: Investigation Details - The investigation focuses on allegations that Super Micro Computer, Inc. made false statements and failed to disclose critical information to investors, including significant sales to companies in China that violated U.S. export control laws [2]. - It is claimed that there were material weaknesses in the company's controls to ensure compliance with applicable export control laws and regulations [2]. - As a result of these issues, the positive statements made by the defendants about the company's business and prospects were misleading and lacked a reasonable basis [2]. Group 2: Shareholder Actions - Shareholders who purchased Super Micro Computer, Inc. shares prior to April 30, 2024, and still hold them can seek corporate reforms and the return of funds to the company at no cost [2][3]. - Interested shareholders are encouraged to visit the provided website or contact the law office for more information on how to proceed with their claims [3].

Core Viewpoint - ImmunityBio, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its lead product, Anktiva, which is claimed to be a cancer treatment but has not demonstrated long-term efficacy as stated by the company [4][5]. Company Overview - ImmunityBio is a biotechnology company focused on developing next-generation immunotherapies, with Anktiva being its lead biologics product [3]. Allegations - The lawsuit alleges that ImmunityBio made false claims about Anktiva, including that it would allow all NMIBC patients to be cancer-free long-term, which has not been proven [4]. - It is claimed that the assertion of Anktiva being a cancer vaccine is false, and the Executive Chairman overstated its capabilities [4]. - A warning letter from the U.S. FDA indicated that promotional materials misbranded Anktiva, leading to a 21% drop in stock price following the news [5]. Legal Process - Investors who purchased ImmunityBio securities during the class period (January 19, 2026, to March 24, 2026) can seek to be appointed as lead plaintiff in the class action lawsuit [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is representing the investors in this class action and has a strong track record in securities fraud litigation, recovering over $916 million for investors in 2025 alone [7].

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc on behalf of investors who purchased its American Depositary Shares during the specified class period, alleging misleading information regarding clinical study results [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague PC, representing investors who bought Mereo ADS from June 5, 2023, to December 26, 2025 [1][2]. - Investors have until April 6, 2026, to seek appointment as lead plaintiff representative of the class [2]. Group 2: Allegations Against Mereo - The complaint claims that Mereo misled investors by raising expectations about the ORBIT and COSMIC studies, which tested setrusumab for Osteogenesis Imperfecta, while concealing that neither study significantly reduced clinical fracture rates compared to control groups [3]. - Following the disclosure of the study results, Mereo's ADS price fell dramatically from $2.31 on December 26, 2025, to $0.29 on December 29, 2025, resulting in a loss of over 87.7% of its value in one day [3]. Group 3: Company Background - Mereo BioPharma Group plc is a biopharmaceutical company based in London, focusing on treatments for rare diseases [2].